Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.25.01 | Thyroid – nodule | ECE2015

Long-term results of US-guided high-intensity focused ultrasound treatment of benign thyroid nodules

Kovatcheva Roussanka , Vlahov Jordan , Stoinov Julian , Zaletel Katja

Introduction: Thyroid nodules can be detected by ultrasound (US) in 20–30% of unselected populations. Various non-surgical techniques such as laser and radiofrequency ablation have been developed to reduce thyroid nodule size. High-intensity focused ultrasound (HIFU) ablation is a new, non-invasive method that has been shown recently. The aim of our study was to assess the long-term efficacy and safety of US-guided HIFU treatment of benign solid thyroid nodules.<p cla...

ea0070ep422 | Thyroid | ECE2020

Ultrasound guided percutaneous laser ablation of thyroid nodules

Bajuk Nataša Bedernjak , Gaberscek Simona , Pirnat Edvard , Zaletel Katja

Background: Thyroid nodule is the most common endocrine disorder with the prevalence of more than 50% in adults. Majority of nodules are small in size and can be detected only by various imaging methods. Thyroid nodules are usually benign, asymptomatic, and do not need treatment. Growing and large symptomatic thyroid nodules are usually treated with thyroidectomy. Novel minimally invasive ablation techniques can be alternative to surgery. Percutaneous laser ablation is causing...

ea0081oc5.2 | Oral Communications 5: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2022

Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS

Jensterle Mojca , Ferjan Simona , Lezaic Luka , Socan Aljaz , Zaletel Katja , Janez Andrej

Background: GLP-1 agonism have the potential to affect gastric emptying (GE), yet the reports for subcutaneous semaglutide, currently the most effective GLP-1 RA approved for weight management, remain inconclusive. It has been demonstrated that semaglutide either had no effect on GE or it delayed GE only within the first hour, without late phase retention. Notably, those conclusions were made by an indirect method of estimation of GE through ingestion, absorption and determina...

ea0084ps2-07-65 | Graves’ Disease 1 | ETA2022

Hyperthyroidism in graves’ disease and subacute thyroiditis and association with cardiovascular events

Bajuk Studen Katica , Sesek Ana , Pirnat Edvard , Zaletel Katja , Gaberscek Simona

Objectives: Overt hyperthyroidism is reported to be associated with an increased mortality risk and an increased risk of cardiovascular (CV) complications such as an acute coronary syndrome requiring percutaneous coronary intervention, ischemic and non-ischemic stroke, atrial fibrillation and venous thromboembolism. Increased rate of acute CV events in the course of hyperthyroidism is well documented in Graves’ disease (GD) but not in subacute thyroiditis (ST). Last year ...

ea0084ps2-10-93 | Nodules & Cancer | ETA2022

Elastography in the assessment of cold solid thyroid nodules

Bedernjak Bajuk Nataša , Bajuk Studen Katica , Pirnat Edvard , Gaberscek Simona , Zaletel Katja

Introduction: The prevalence of thyroid nodules detected by ultrasound (US) is up to 50% in general population and approximately 5−10% of them is malignant. Diagnostic assessment includes laboratory tests thyroid US and thyroid scintigraphy, where suspicious nodules are characteristically cold when using99m Tc-pertechnetate as a tracer. A useful tool for US-based risk stratification of thyroid nodules is Thyroid Imaging Reporting and Data System (TIRADS). Rece...

ea0084ps3-12-108 | Graves’ Disease 2 and Orbitopathy | ETA2022

The incidence and risk factors of radioiodine-induced graves’ disease following treatment of thyroid autonomous tissue

Zaletel Tjaša , Rot Živa , Krkovic Danijela , Gaberscek Simona , Zaletel Katja

Introduction: Radioiodine (I-131) therapy is an effective treatment for thyroid autonomy but may induce Graves’ disease (GD) but in up to 5% of patients. GD is characterised by antibodies against TSH receptor (TSHRAb). We set out to evaluate the incidence and risk factors of I-131-induced GD in patients with thyroid autonomy treated with I-131.Methods: We retrospectively reviewed patients with solitary toxic adenoma or toxic nodular goiter who were ...

ea0092ps2-15-06 | Hyperthyroidism | ETA2023

Factors influencing early outcome of radioiodine treatment in patients with graves’ disease

Pirnat Edvard , Zaletel Tjaša , Rot Živa , Gaberscek Simona , Zaletel Katja

Aim: In Graves’ disease (GD) the goal of radioiodine (I-131) application is the elimination of hyperthyroidism. The reported success rate 1 year after treatment is up to 90%. The aim of this retrospective study was to assess the factors influencing the early outcome 3 months after I-131 treatment of GD patients in an iodine sufficient area.Materials and Methods: We reviewed medical records of GD patients who received I-131 therapy between January 20...

ea0084ps2-10-92 | Nodules & Cancer | ETA2022

Incidence of non-diagnostic and undetermined cytologies in ultrasound-guided fine needle aspiration biopsy specimens of thyroid nodules – a single-center cohort

Vendramin Andreja , Zupanc Davorin , Pirnat Edvard , Zaletel Katja , Bedernjak Bajuk Nataša , Bajuk Studen Katica , Jesenko Miha , Gaberšček Simona

Objectives: Ultrasound-guided fine needle aspiration biopsy (FNAB) is a commonly performed diagnostic procedure for evaluation of thyroid nodules. The Bethesda System for Reporting Thyroid Cytopathology comprises six categories. Bethesda categories I and III present a challenge for deciding on further diagnostic and therapeutic procedures. Category I includes non-diagnostic or unsatisfactory results that may be due to both aspiration of cystic material from simple cysts or asp...

ea0090p656 | Endocrine-related Cancer | ECE2023

Management of NENs with SSTR2-antagonist: how close are we to a clinical solution? The first results of the TECANT study: Novel 99m-Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms – a feasibility study

Hubalewska-Dydejczyk Alicja , Decristoforo Clemens , Kolenc Petra , Mikolajczak Renata , Ležaić Luka , Suden Andrej , Garnuszek Piotr , Simoncic Urban , Virgolini Irene , Trofimiuk-Muldner Malgorzata , Opalinska Marta , Rangger Christine , Glowa Boguslaw , Skorkiewicz Konrad , Fani Melpomeni , Sowa Staszczak Anna , Janota Barbara , Kroselj Marko , Zaletel Katja , Von Guggenberg Elisabeth

Introduction: The management of patients with neuroendocrine neoplasms (NEN) has been revolutionised since the introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SSTR). Accurate assessment of SSTR status of primary focus/metastases is crucial to determine the choice of the treatment method. Recently it has been shown that novel molecular probes, SST2-antagonists, recognize more binding sites in comparison to the wide...

ea0049ep1445 | Thyroid (non-cancer) | ECE2017

Theranostic management of medullary thyroid cancer (MTC) with (111In/177Lu) CP04: how close are we to a clinical solution?

Hubalewska-Dydejczyk Alicja , Erba Paola , Decristoforo Clemens , Zaletel Katja , Mikolajczak Renata , Maecke Helmut , Maina-Nock Theodosia , Konijnenberg Mark , Kolenc-Peitl Petra , Trofimiuk-Muldner Malgorzata , Przybylik-Mazurek Elwira , Virgolini Irene , Pawlak Dariusz , de Jong Marion , Froberg Alide C , Rangger Christine , Goebel Georg , Scarpa Lorenza , Skorkiewicz Konrad , Lezaic Luka , Garnuszek Pirotr , Sowa-Staszczak Anna , Nock Berthold A , Bergant Damijan , Rep Sebastijan , Glowa Boguslaw

Effective targeted therapy for advanced endocrine malignancies is a goal of modern endocrinology. We herein present promising results of the first phase of clinical part of European project (Gran-T-MTC) aimed to assess the safety of gastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) i.v. administration in dose (50 μg) useful for translation to 177In-CP04 for PRRT. CP04 has been selected for MTC therapy based on a high CCK-2 receptor...